163 related articles for article (PubMed ID: 19157545)
1. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.
Steensma DP; Porcher JC; Litzow MR; Hogan WJ; Arora S; Van Laar ES
Leuk Res; 2009 Jul; 33(7):e81-2. PubMed ID: 19157545
[No Abstract] [Full Text] [Related]
2. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B
Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902
[No Abstract] [Full Text] [Related]
3. Treating myelodysplastic syndrome when hypomethylating agents stop working.
Jabbour E
Clin Adv Hematol Oncol; 2014 Apr; 12(4):257-9. PubMed ID: 25003355
[No Abstract] [Full Text] [Related]
4. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
[No Abstract] [Full Text] [Related]
6. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
7. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
8. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes (MDS).
Klimek V
Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
[No Abstract] [Full Text] [Related]
10. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
11. Decitabine.
Gore SD; Jones C; Kirkpatrick P
Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
[No Abstract] [Full Text] [Related]
12. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
13. Decitabine in myelodysplastic syndromes: viewpoints.
Garcia-Manero G; Saba HI
Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
[No Abstract] [Full Text] [Related]
14. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
Rüter B; Wijermans P; Claus R; Kunzmann R; Lübbert M
Blood; 2007 Aug; 110(3):1080-2; author reply 1083. PubMed ID: 17644749
[No Abstract] [Full Text] [Related]
15. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
16. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
19. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
Shao XR; Liang H; Guan XJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
[No Abstract] [Full Text] [Related]
20. Therapy with azanucleosides for myelodysplastic syndromes.
Quintás-Cardama A; Santos FP; Garcia-Manero G
Nat Rev Clin Oncol; 2010 Aug; 7(8):433-44. PubMed ID: 20551943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
